The proteome undertakes many cellular physiological activities, and proteomics enables the discovery of a vast majority of drug-targetable proteins. Compared to the genome, the proteome is more representative to reflect the precise state of disease and provides invaluable information for precision medicine. Thus, studies using proteomics as a tool facilitate cancer diagnosis and the development of personalized medicine for cancer patients. In the post-genomic era, precision medicine faces challenges in the identification of biomarkers, systematic description of pathogenic mechanisms, and accurate evaluation of efficacy. Proteomics can accurately identify drug targets and realize effective diagnosis and prognosis evaluation of diseases.
Despite progress in treatment including surgery, radiation, and chemotherapy, the prognosis for this devastating disease remains dismal. The malignant properties of brain tumors such as fast and aggressive growing result in incomplete removal by surgery. Due to the existence of blood-brain barrier, radiation and chemotherapy show limited treatment effects, which leads to serious threats to the patient's life. Especially, one of the most fatal brain tumors in adults is glioblastoma (WHO IV, GBM), and the median survival of GBM patients is limited to 14.6 months. There is an urgent need for proteomics research and targeted therapy to break the emerging therapeutic dilemma of malignant brain tumors. In addition, understanding the brain tumor microenvironment and cancer stem cells based on proteomics studies will shed light on novel therapeutic approaches.
Over the past decade, great advances have been made in the field of precision medicine in treating different types of cancers, including glioblastoma. Results from many large-scale studies show that the expression levels of proteins are not necessarily consistent with their corresponding DNA or mRNA copy numbers. As proteins are a direct functional carrier of cellular activity, investigations of cancer cells using proteomics provide direct targets for diagnosis and treatment. Proteomics studies provide comprehensive data to facilitate accurate classification of disease, early diagnosis, therapeutic targets identification, treatment plan, and prognosis evaluation.
The purpose of this Research Topic is to focus on screening and identifying new targets for diagnosis, treatment, and prognosis of malignant brain tumors (including primary pediatric brain tumors) by mass spectrometry or proteomic-related technologies, and to elucidate their mechanisms for promoting or inhibiting cancer development. At the same time, we are also interested in understanding brain tumor biology through the aspects of translational medicine, drug repurposing studies, cancer stem cells, tumor microenvironment. Altogether, our research topics will focus on proteomics and brain tumor-related studies and translational/translatable studies.
• Screening and identification of key proteins of malignant brain tumors as diagnosis, treatment, and prognosis targets by use of mass spectrometry and proteomic related techniques
• The exploration of targeted therapy and mechanism analysis of key proteins in malignant brain tumors
• Drug repurposing in malignant brain tumors
• Proteomics studies of the microenvironment of malignant brain tumors
• Studies on the proteomics of secondary malignant brain tumors in adults is not in the scope of this Research Topic
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The proteome undertakes many cellular physiological activities, and proteomics enables the discovery of a vast majority of drug-targetable proteins. Compared to the genome, the proteome is more representative to reflect the precise state of disease and provides invaluable information for precision medicine. Thus, studies using proteomics as a tool facilitate cancer diagnosis and the development of personalized medicine for cancer patients. In the post-genomic era, precision medicine faces challenges in the identification of biomarkers, systematic description of pathogenic mechanisms, and accurate evaluation of efficacy. Proteomics can accurately identify drug targets and realize effective diagnosis and prognosis evaluation of diseases.
Despite progress in treatment including surgery, radiation, and chemotherapy, the prognosis for this devastating disease remains dismal. The malignant properties of brain tumors such as fast and aggressive growing result in incomplete removal by surgery. Due to the existence of blood-brain barrier, radiation and chemotherapy show limited treatment effects, which leads to serious threats to the patient's life. Especially, one of the most fatal brain tumors in adults is glioblastoma (WHO IV, GBM), and the median survival of GBM patients is limited to 14.6 months. There is an urgent need for proteomics research and targeted therapy to break the emerging therapeutic dilemma of malignant brain tumors. In addition, understanding the brain tumor microenvironment and cancer stem cells based on proteomics studies will shed light on novel therapeutic approaches.
Over the past decade, great advances have been made in the field of precision medicine in treating different types of cancers, including glioblastoma. Results from many large-scale studies show that the expression levels of proteins are not necessarily consistent with their corresponding DNA or mRNA copy numbers. As proteins are a direct functional carrier of cellular activity, investigations of cancer cells using proteomics provide direct targets for diagnosis and treatment. Proteomics studies provide comprehensive data to facilitate accurate classification of disease, early diagnosis, therapeutic targets identification, treatment plan, and prognosis evaluation.
The purpose of this Research Topic is to focus on screening and identifying new targets for diagnosis, treatment, and prognosis of malignant brain tumors (including primary pediatric brain tumors) by mass spectrometry or proteomic-related technologies, and to elucidate their mechanisms for promoting or inhibiting cancer development. At the same time, we are also interested in understanding brain tumor biology through the aspects of translational medicine, drug repurposing studies, cancer stem cells, tumor microenvironment. Altogether, our research topics will focus on proteomics and brain tumor-related studies and translational/translatable studies.
• Screening and identification of key proteins of malignant brain tumors as diagnosis, treatment, and prognosis targets by use of mass spectrometry and proteomic related techniques
• The exploration of targeted therapy and mechanism analysis of key proteins in malignant brain tumors
• Drug repurposing in malignant brain tumors
• Proteomics studies of the microenvironment of malignant brain tumors
• Studies on the proteomics of secondary malignant brain tumors in adults is not in the scope of this Research Topic
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
